In August 2020, Teladoc and Livongo told investors their merger would create a global leader in consumer-centered virtual care. Livongo brought chronic-condition coaching and Applied Health Signals; Teladoc brought a global virtual-care platform. The pitch was that one combined company could serve the whole person, from prevention to complex cases.
That bet landed at the top of the telehealth boom. By 2022, Teladoc's own SEC facts showed $2.41 billion of annual revenue, but a net loss of $13.66 billion. Almost all of the red ink came from goodwill: Teladoc recorded a $13.40 billion goodwill impairment for the year.
The write-down did not mean every acquired product vanished. It meant the price paid for pandemic-era growth no longer matched the cash flows and market multiples the business could support. A strategic story about combining care journeys became an accounting admission that the acquired goodwill was worth far less than booked.
Teladoc wrote down $13.40B of goodwill after paying pandemic-era prices for Livongo, turning a $2.41B revenue year into a $13.66B net loss.
Teladoc bought a chronic-care growth story when telehealth valuations were inflated by pandemic demand.
The merger logic depended on cross-selling a broad whole-person care platform, not merely keeping Livongo's diabetes-coaching product alive.
Goodwill carried the deal's optimism on the balance sheet until lower market multiples and cash-flow expectations forced a $13.40B impairment.
The company still had $2.41B in 2022 revenue, but the $13.66B net loss showed how acquisition accounting can swamp operating scale.
A platform acquisition priced for a temporary demand spike can survive operationally and still fail financially when the goodwill math catches up.
FOLLOW THE EVIDENCE